Young-onset dementia: scoping review of key pointers to diagnostic accuracy by O'Malley, Mary et al.
Review
Young-onset dementia: scoping review
of key pointers to diagnostic accuracy
Mary O’Malley, Jacqueline Parkes, Vasileios Stamou, Jenny LaFontaine, Jan Oyebode and Janet Carter
Background
Routine psychiatric assessments tailored to older patients are
often insufficient to identify the complexity of presentation in
younger patients with dementia. Significant overlap between
psychiatric disorders and neurodegenerative diseasemeans that
high rates of prior incorrect psychiatric diagnosis are common.
Long delays to diagnosis, misdiagnosis and lack of knowledge
from professionals are key concerns. No specific practice
guidelines exist for diagnosis of young-onset dementia (YOD).
Aims
The review evaluates the current evidence about best practice in
diagnosis to guide thorough assessment of the complex pre-
sentations of YOD with a view to upskilling professionals in the
field.
Method
A comprehensive search of the literature adopting a scoping
review methodology was conducted regarding essential ele-
ments of diagnosis in YOD, over and above those in current
diagnostic criteria for disease subtypes. This methodology was
chosen because research in this area is sparse and not amen-
able to a traditional systematic review.
Results
The quality of evidence identified is variable with the majority
provided from expert opinion and evidence is lacking on some
topics. Evidence appears weighted towards diagnosis in
frontotemporal dementia and its subtypes and young-onset
Alzheimer’s disease.
Conclusions
The literature demonstrates that a clinically rigorous and
systematic approach is necessary in order to avoid mis- or
underdiagnosis for younger people. The advent of new disease-
modifying treatments necessitates clinicians in the field to
improve knowledge of new imaging techniques and genetics,
with the goal of improving training and practice, and highlights
the need for quality indicators and alignment of diagnostic
procedures across clinical settings.
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Young-onset dementia (YOD), arbitrarily described as dementia
diagnosed under 65 years, is poorly recognised and often misdiag-
nosed.1,2 This clinical review evaluates the current evidence about
best practice in diagnosis to guide thorough assessment of the
complex presentations of YOD.
Many clinical practice guidelines on thediagnosis andmanagement
of dementia exist, but vary in the grading systems used to assess the
quality of evidence and the strength of recommendations.3 There are
currently no specific practice guidelines about diagnosis in YOD
although excellent practice pointers specific to key areas are avail-
able.4–6 The differential diagnosis of YOD encompasses complex pre-
sentations of the common primary neurodegenerative diseases as well
as autoimmune, inflammatory, late-onset metabolic and hereditary/
familial causes.5 Although Alzheimer’s disease makes up the majority
of cases, it represents a significantly smaller percentage than in late-
onset Alzheimer’s disease (LOAD) and presentations are frequently
non-amnestic in nature.7
Heterogeneity of presentation in YOD
Dementia diagnosis is dominated by the traditional view, derived
from the numerical dominance of LOAD, that all dementia is asso-
ciated with episodic memory loss and functional decline. For some
clinicians in general practice, adult psychiatry and older adult
memory services, atypical presentations of the common dementias
in younger people are rarely encountered and this can result in delay
to referral, clinical underinvestigation, misdiagnosis and delays in
obtaining a definitive diagnosis.8,9
For example, one in three people with young-onset Alzheimer’s
disease present with problems associated with posterior cortical
atrophy (PCA). Rather than reporting memory problems, that are
more typical of LOAD,10 those with PCA experience problems
with object recognition and other visual changes. Autosomal dom-
inant forms of frontotemporal dementia (FTD) and Alzheimer’s
disease are also common and may present with neurological symp-
toms.11 People with behavioural variant FTD (bvFTD), may start to
show lack of empathy or concern for others, and social disinhib-
ition, such as being overfamiliar with strangers or acting on aggres-
sive or appetitive urges, by swearing or overeating sweet foods.12
Changes in managing complex tasks may be identified by indivi-
duals becoming apathetic, perseverative or failing to plan ahead.
Similarly, those with primary progressive aphasias13 are likely to
experience various problems with language, for example retaining
meaning of words, producing or finding words. None of these dif-
ficulties are well-captured through most of the common cognitive
screening tests for dementia, as these are focused predominantly
on testing orientation and memory.
Biological differences in YOD
In addition to issues of heterogeneity, emerging evidence confirms
distinct biological differences between LOAD and young-onset
Alzheimer’s disease, with the latter having greater neocortical path-
ology, particularly in the parietal cortex, greater tau compared with
amyloid burden, and less hippocampal disease.11 Recent analysis
suggests that an age cut-off of 70 provides better differentiation on
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neuropsychology testing between early- and late-onset Alzheimer’s
disease than the standard cut-off of 65 years old.14 There is also
emerging evidence of younger people with bvFTD having sig-
nificantly higher rates of disinhibition, more loss of sympathy/
empathy and more perseverative, compulsive behaviours compared
with those with late onset.15 Thus, the evidence suggests that effect-
ive diagnosis of YODmust be guided by differences that distinguish
it from late-onset disease, and also encompass the inherent hetero-
geneity within a younger population.16
Delays to diagnosis and misdiagnosis
Evidence regarding delays to diagnosis has identified that although60%
of young-onset patients sought help within 12 months of symptom
onset,17 it took an average of 3.3 years in a young-onset Alzheimer’s
disease group and 4.9 years in a young-onset FTD group to receive a
formal diagnosis.18 More recent studies, indicate that the average
time todiagnosiswas 4.4 years in younger people for all-cause dementia
comparedwith 2.2 years for late-onset disease of comparable severity.19
Increased time to diagnosis for younger people, is more likely when the
younger person receives a diagnosis of FTD, rather thanother dementia
types.20 Given the significance of changes in empathy and disinhibition
often associated with FTD, delay in diagnosis can mean that close
relationships break down prior to diagnosis or that people take consid-
erable risks.Additionally, the time todementia diagnosis is significantly
longer when the dementia is other than Alzheimer’s disease or FTD.21
The INSPIRED (Improving Services for Younger Onset Memory and
Related Disorders) study from Australia recently reported time to
final diagnosis of the type of dementia from first presentation as 4.7
years.20 Participants with younger onset experienced significantly
longer time to first consultation and to family awareness of the demen-
tia diagnosis.22
Psychiatric presentation
Atypical presentations of YOD frequently overlap with psychiatric
conditions resulting in misdiagnosis as a psychiatric illness preceding
final diagnosis of YOD, accounting for 28% of individuals presenting
to a specialist clinic in a retrospective masked chart review study.23
The consequences of misdiagnosis include delay to diagnosis, use
of ineffective and potentially harmful treatments, delays to getting
appropriate support and increased family stress.24 Furthermore,
several studies1,2,25 have evaluated the quality of the diagnostic
work-up in patients aged 65 years and younger using evidence-
based guidelines for the diagnostic evaluation of dementia as reference
standards including as a minimum: history of cognitive symptoms,
cognitive testing, psychiatric evaluation, physical examination includ-
ing neurological examination, assessment of activities of daily living, a
battery of blood tests, electrocardiogram and computed tomography
ormagnetic resonance imaging (MRI) scan of the brain. An acceptable
diagnostic work-up including all items of recommended basic diag-
nostic evaluation was performed in only 24%.1
The aim in this review is to inform the debate regarding the essen-
tial elements of the diagnostic process in YOD, over and above the use
of current diagnostic criteria for disease subtypes and to identify
current advances and research findings in preparation for an inter-
national Delphi consensus on diagnosis of YOD funded by the
Alzheimer’s Society. It is not intended to provide an overview of
key features and assessment of the main neurodegenerative condi-
tions that are covered comprehensively elsewhere.6,26–29
Method
A comprehensive search of the literature, adopting a scoping review
methodology30 was conducted, and updated in September 2018.
Two electronic search engines were used: PubMed and Web of
Science. We focused only on research articles that had been pub-
lished in peer-reviewed journals to ensure the evidence base and
methodology used was rigorous. The databases were selected as
they particularly cover life science and biomedical fields of research
and allowed us to focus on whether our key search terms were found
in the highlighted papers’ abstracts.
Search strategy and selection criteria
Systematic and concise terms were used to search for relevant
papers (see Appendix 1 for details of the terminology). The terms
groups were combined using Boolean operators, using the AND
function in the following manner: 1 AND 2 AND 3.
Additional inclusions
The initial search was conducted on 16 June 2017, to include papers
published between the years 2012 and 2017. On 12 September 2018
the search was re-run and updated using the original search terms to
establish if any additional papers had been published; therefore, the
search included papers published between 16 June 2012 and
12 September 2018. Studies conducted internationally (i.e. outside
of the UK) were included, although only if the articles were
written in English. Database search strategies were supplemented
with snowballing methods,31 including reference list and citation
searches, author searches and hand searching of key journals.
Exclusion criteria
The exclusion criteria were as follows.
(a) Studies focused on Korsakoff/alcohol-induced dementia or
dementia caused by HIV/AIDS, as these conditions tradition-
ally have different pathways to diagnosis and care.
(b) Dementia research solely focused on late-onset dementia, as
these would not reflect YOD.
(c) Articles concerning late-onset dementia.
(d) Papers related to psychosocial approaches and basic neuroscience.
(e) Articles focused solely on qualitative reports about the experi-
ence of assessment and diagnosis from people living with
YOD.
Two reviewers (J.C. and M.O.M.) independently screened titles and
abstracts identified by the search and applied the selection criteria to
potentially relevant papers. The full texts that were appropriate and
included in the review following initial abstract screening were then
read in full by the same two authors.
Data extraction
Our data extraction process involved removing duplicated papers
from the two separate databases, including any additional papers
found through protocol-driven strategies. All abstracts were
reviewed for whether they met criteria, and full texts were read
for those remaining papers. After reading the 55 full-texts, 23 arti-
cles were rejected as it was discovered upon reading that they did not
meet our exclusion criteria. In total 29 papers met criteria and were
included (see Fig. 1).1,2,11,14,20,23,25–29,33–35,42,46,47,51,52,54,58,60,62,64–68,70
Results
The 29 papers were grouped into themes related to the standard
clinical approach to diagnostic assessment, i.e. history taking, phys-
ical examination, investigation and diagnosis. A summary of key
pointers for the clinical assessment is outlined in Appendix 2.
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History taking
The majority of papers related to traditional methods of clinical
history taking (see Appendix 2). However, Snowden et al, identified
that a guided, more structured approach to diagnosis in identifying
Alzheimer’s disease and FTDs in younger people leads to higher
correlation with post-mortem findings.33 In this approach, consid-
eration of time course of the illness, pattern of physical, behavioural
and cognitive symptoms, comparison of anterior versus posterior
cognitive deficits and specificity of cognitive deficits, for example
non-focal or focal, yielded high specificity and sensitivity (FTD
97% and 100%, respectively; Alzheimer’s disease 100% and 97%,
respectively) where supplementary neuroimaging had been unhelp-
ful. Within this broad framework, the importance of taking a collat-
eral history from an informant/family member was generally
emphasised27,28,32,33 but felt to be particularly salient in those pre-
senting with non-cognitive behavioural problems or personality
change that might indicate a diagnosis of FTD.
When eliciting key symptoms, most research has focused pri-
marily upon discrimination of FTD from Alzheimer’s disease. Key
areas, namely, stereotypic or ritualistic behaviour (such as clock-
watching, stereotyped use of catch-phrases, preoccupation with
counting and numbers), appetite increase and change in preference
for sweet food, disinhibition, and features of poor social awareness
have been shown to reliably separate groups with FTD from those
with Alzheimer’s disease on factor analysis of a carer-rated scale
of neuropsychiatric symptoms for assessment of patients where
conventional cognitive tests are unlikely to be discriminatory.54
The suggested use of open-ended questions during history taking
such as ‘has the patient said or done anything embarrassing?’,
‘does he or she seem indifferent/obsessive or less affectionate?’
may help elucidate these key symptoms.26,27 For Alzheimer’s
disease, detailed understanding of key features may help. For
example, in the absence of a reliable family history, a retrospective
cohort study of familial and non-familial early-onset Alzheimer’s
disease with the commonest PSEN1 mutation identified the follow-
ing clinical characteristics as key features that may aid discrimin-
ation; an early and progressive age at onset, history of headaches,
myoclonus, gait abnormalities and pseudobulbar affect.34
Family history
A history of familial disease is particularly relevant in YOD as famil-
ial forms of neurodegeneration are more frequent in this age group.
Taking a clear family history of dementia or other neurological dis-
eases is advocated, in particular the use of a detailed family history of
at least three generations.26 High risk, indicating the need for
genetic testing, may be indicated by a history of one affected relative
in the case of FTD35 and two first-degree relatives with early-onset
Alzheimer’s disease in the Alzheimer’s disease.53 One should note
that this information may be insufficient for those who lack a
known or reliable family history and be masked in those with
small families and premature death because of other causes. A com-
prehensive overview of approaches to genetic testing and counsel-
ling in YOD is beyond the scope of this review and is available
elsewhere.35
Psychiatric history
Psychiatric evaluation can identify behavioural and psychological
symptoms that are common and contribute to patient distress
and care burden.1 However, very limited attention has been given
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Fig. 1 Screening and literature selection procedure.
YOD, young-onset dementia; LOD, late-onset dementia.
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to the importance of psychiatric assessment and development or use
of appropriate tools despite clear evidence of frequent presentation
of younger people living with dementia (YPD) to psychiatric ser-
vices. High rates of psychiatric misdiagnosis are driven by the sig-
nificant overlap in symptoms of neurodegenerative disease
especially bvFTD and psychiatric disorders.55 In one study, 28%
of individuals with a neurodegenerative disease had a prior incorrect
psychiatric diagnosis.23 Across groups, depressive disorders and
bipolar affective disorder were the most common misdiagnoses
although a diagnosis of schizophrenia was not uncommon. Rates
ranged from <12% in those with atypical presentations such as
prominent language, speech or movement disorders and up to
52% in those with bvFTD.23 Over 50% of patients waited up to 3
years before the diagnosis was revised. Although onset in 30 s and
40 s may overlap with age at onset for a psychotic disorder, lack
of first-rank symptoms and a clear family history, often autosomal
dominant in nature, of a neurodegenerative condition should raise
suspicion of a neurodegenerative condition.
Younger age at symptom onset, limited education and a strong
family history of psychiatric illness are significantly associated with
prior psychiatric misdiagnosis in bvFTD. The key features at pres-
entation identified by clinicians as suggesting a functional rather
than organic aetiology were emotional symptoms and eating symp-
toms often leading to misdiagnosis of those with FTD as having
major depressive disorder.23 Equally, apathy, social withdrawal
and lack of initiation may be mis-identified as depression.56 As
aids to discrimination, the ritualistic and impulsive behaviours of
bvFTD usually lack the anxiety of obsessive–compulsive disorders,
and dietary changes such as overeating with dramatic weight gain
are uncharacteristic of depressive disorders. Similarly, history of
longstanding delusions, command auditory as opposed to visual
hallucinations, intermittent history of anxiety and depression,
hypomanic episodes and distressing compulsions impacting on
day-to-day life are more indicative of primary psychiatric illness.
The use of a structured carer-based questionnaire such as the
Neuropsychiatric Inventory can be helpful to capture changes in
behaviour and to assist diagnostic accuracy.39 Neuropsychiatric
symptoms have a significant impact on patients and supporters
and represent the main predictor of a move to institutional care.57
Recently, discovery of the C9orf72 mutation associated with
bvFTD has focused upon psychosis as a presenting psychiatric
symptom in FTD, which may occur years before dementia
onset.53 Psychotic symptoms are not included in current diagnostic
criteria for FTD. A recent review, based on 122 publications, con-
cluded that the approximate prevalence of psychotic symptoms in
FTD is 10%.55 Among those with a known genetic background,
psychotic symptoms have been found to be especially common in
both progranulin and C9orf72 carriers with reported prevalence of
25% of progranulin mutation carriers58 and around 50% or more
in C9orf72.59 Misdiagnosis of patients carrying the C9orf72 muta-
tion with a psychiatric diagnosis (e.g. schizophrenia) is reported
and this may be particularly problematic for those patients with
no neurological signs to orientate diagnosis.
Overall, the evidence suggests that a high index of suspicion is
necessary for younger and mid-life patients who present with
new-onset depressive, behavioural, psychotic or cognitive symp-
toms.23 Additional assessment pointers to avoiding misdiagnosis
as psychiatric illness include re-evaluation of previously diagnosed
treatment-resistant depression that may be a proxy for comorbid
dementia.20
Physical and neurological examination
No specific guide to neurological examination in YOD is available in
the literature but good clinical practice would suggest that thorough
neurological examination accompanied by physical examination is a
vital part of the approach to accurate diagnosis. Although, typically
unremarkable, early identifying clues to possible diagnoses may
include apraxia, parkinsonism, upper and lower motor neuron
symptoms, eye signs, cerebellar signs, extrapyramidal signs and
frontal release signs.5,6,32
Investigations
Neuropsychology and cognitive assessment
Neuropsychology testing acts as a gatekeeper to more extensive
investigations and provides objective evidence of cognitive deficit.
Generally, more subtle approaches to cognitive assessment are
required in YOD and measures such as the Montreal Cognitive
Assessment43 and Addenbrookes Cognitive Examination44 may be
unhelpful. More accurate assessment may be enhanced by the use
of appropriate assessment tools. For example, there is increasing
recognition that bvFTD may have an amnestic component,
making it more difficult to distinguish from Alzheimer’s disease,
despite diagnostic guidelines. Several studies indicate that in the
absence of cerebrospinal fluid (CSF) biomarkers and amyloid posi-
tron emission tomography (PET) imaging, social cognition tools
(such as, the (Mini) Social Cognition and Emotional Assessment
Tool) may be more useful in distinguishing bvFTD from
Alzheimer’s disease.41 In addition, the Frontal Assessment
Battery45 that tests for a number of cognitive changes associated
with FTD (conceptualisation, mental flexibility, motor program-
ming, sensitivity to interference, inhibitory control and environ-
mental autonomy) may be useful for eliciting clinical symptoms.
Recent studies support a differentiated pattern of neuropsycho-
logical impairment in some dementia subtypes according to age. For
example, Palasi et al showed that patients with young-onset
Alzheimer’s disease performed worse than those with LOAD in
attentional, imitation praxis and verbal learning tests, and that an
age cut-off of 70 differentiated between early- and late-onset
groups better than the standard cut-off of 65 years old.14 These find-
ings emphasis that scoring thresholds may need to be adapted on
routine neuropsychological test batteries when administered to
younger adults.
Furthermore, despite current diagnostic criteria for FTD, at
least in the early stages, the traditional view of episodic memory
impairment in young-onset Alzheimer’s disease and language and
executive dysfunction in FTD may not be a useful discriminatory
factor and a more comprehensive assessment is necessary.46,47 In
a large comparison of neuropsychological data in pathologically
confirmed cases of Alzheimer’s disease and FTD, the neuropsycho-
logical test battery of the Uniform Data Set,60 which is essentially a
standard test battery, with the exception of memory, did not separ-
ate cognitive performance across the two groups. This raises the
issue of whether in the absence of specific biomarkers, standard
neuropsychological test batteries, used frequently in memory
clinics, contribute to accurate diagnosis and indicate that more tai-
lored approaches are essential. Many tests of cognitive impairment
are used in memory clinics without having been validated in popu-
lations under 65.61
Biomarkers
Neuroimaging. Neuroimaging remains a crucial first-line investi-
gation in diagnosis of all types of dementia. MRI is considered the
preferred modality to aid differential diagnosis or exclude diagnoses
often by aiding assessment of patterns of atrophy.29,62 Advances in
techniques and image analysis increasingly support the inclusion of
more specialised imaging protocols as a key biomarker in diagnosis
of YOD although translation into use in everyday clinical practice is
lacking. Medial temporal lobe atrophy is recognised as a supportive
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biomarker for the diagnosis of Alzheimer’s disease. The medial tem-
poral lobe atrophy (MTA) scale is the commonest visual rating scale
of hippocampal atrophy in Alzheimer’s disease and its use extends
to clinical practice in some settings.63 The cut-off used for the scale
is critical to discriminate disease from ‘non-cases’. However, for
Alzheimer’s disease in younger populations, where presentations
with PCA are more common, the Posterior Atrophy scale in com-
bination with the MTA scale may aid discrimination.64 It may
also have a role to discriminate Alzheimer’s disease from FTD
and enhance diagnosis of focal Alzheimer’s disease presentations
in a younger group where MTA may be absent.7
An analysis of three different visual rating scales looking at sen-
sitivity and specificity of MTA cut-off scores suggested that adjust-
ment of cut-offs according to age would help further with diagnostic
accuracy in younger populations.63,64 However, more clinically real-
istic, as such sophisticated techniques are generally only available in
major centres, visual inspection by an experienced neuroradiologist
has equally been demonstrated to be highly correlated with patho-
logically confirmed diagnosis.48 Similarly, normal MRI in cases of
clinically severe dementia should prompt reconsideration of
diagnosis.
Clinical use of molecular imaging. The growing evidence base for
molecular imaging has led to the introduction of clinical guide-
lines65 recommending the use of fluorodeoxyglucose (FDG)-PET
or single-photon emission computer tomography (SPECT), princi-
pally, for all individuals with early-onset cognitive decline and for
prominent non-amnestic presentations involving language, visuo-
spatial, behavioural executive and/or non-cognitive symptoms in
Alzheimer’s disease or prominent amnestic presentation in non-
Alzheimer’s disease dementias. Although only a few studies are
available with evidence about specificity and sensitivity of
FDG-PET and SPECT in atypical Alzheimer’s disease, the
European federation of the Neurological sciences recommend
their use when diagnosis is in doubt after structural imaging and
clinical work-up.4 Similarly the use of amyloid PET imaging is advo-
cated in young-onset Alzheimer’s disease presenting with non-
amnestic symptoms, in patients presenting with clinically atypical
presentations, and in differentiation of Alzheimer’s disease from
FTD as the latter is not associated with amyloid deposition in
younger patients.4,66,67 Additionally, the guidelines suggest that
there is value in functional imaging in those with severe cognitive
impairment in psychiatric disease or where cognitive testing is
not possible.
CSF biomarkers. Three types of biological marker are found in
CSF and are currently in use: Aβ1–42 amyloid protein, total tau
(T-tau) and phosphorylated tau (P-tau), tau proteins. Although
many published studies suffer from a lack of masking and patho-
logical confirmation of diagnosis, the lower frequency of mixed
pathology in younger people and the reduced likelihood of patho-
logical change in CSF compared with older patients has led to the
suggestion that positive Alzheimer’s disease CSF biomarkers may
be most useful in diagnosis of YOD.51 The National Institute of
Ageing–Alzheimer’s Association criteria for Alzheimer’s disease
dementia recognises the importance of positive Alzheimer’s
disease CSF biomarkers in research diagnostic criteria guidelines
but suggests that challenges in achieving required sensitivity and
specificity, and centre-to-centre variability, precludes their use in
clinical practice. Conversely, the Alzheimer’s biomarkers standard-
isation initiative52 reached consensus that Alzheimer’s disease CSF
biomarker analysis be considered as a routine clinical test in all
early-onset dementia, atypical or complex presentations. Given
the variation in attitudes and use of CSF biomarkers, it has been sug-
gested that developing consensus guidelines on CSF-related
methodologies and how they are applied clinically would be benefi-
cial.68 The new National Institute for Health and Care Excellence
guidelines in 2018 outline the value of FDG-PET or perfusion
SPECT and/or CSF biomarkers in a systematic approach to identi-
fying specific dementia subtypes.69
There is currently no conclusive head-to-head comparison
study of amyloid PET imaging in early versus late-onset disease,70
and no firm evidence regarding a hierarchy of implementation
with regard to CSF markers versus amyloid PET71 to guide clinical
practice. ‘Appropriate use’ criteria for amyloid PET imaging in
patients with progressive dementia and atypically young age49,50
support its value.
Discussion
Prevalence figures for the numbers of people with YOD in most
countries (including the UK) are lacking, presenting a significant
hurdle to adequate provision of specialist services. Patient groups
continue to express concerns about long delays to diagnosis, lack
of knowledge from key professionals, lack of continuity of care
and limited information at the time of diagnosis.72 Equally,
because the majority of dementia services remain primarily
focused upon the needs of older people, gaining access to age-appro-
priate post-diagnosis interventions remains challenging for younger
people.73
YOD presents a significant diagnostic challenge and atypical
presentations and overlap with psychiatric syndromes are
common. This complexity often results to delays in diagnosis and
additional stress, frustration and burden for families. The evidence
confirms that YPD see on average a minimum of two and some up
to five different specialists before receiving a final diagnosis and
pathways into care in the UK are chaotic.73 Typically, many YPD
have lost their jobs before the opportunity for reasonable adjust-
ments and vocational rehabilitation in the workplace and there
are attendant economic costs of unnecessary appointments, poten-
tially ineffective treatments and loss from the work force of family
members.
Providing an accurate diagnosis is the first stage in allowing
families access to treatment and support and help reduce uncer-
tainty about the future. The majority of younger people in the UK
continue to be assessed and diagnosed in mental health-led
memory clinics where limited access to other disciplines is well
documented.73 Furthermore, clear advice on a best practice
approach to ascertaining diagnosis in younger patients is lacking.
This raises concern as many dementia/memory clinics continue to
employ routine procedures, screening measures and cognitive
tests tailored to older patients that are often insufficient to identify
the complexity of presentation in YPD and result in underinvestiga-
tion with limited use of crucial supplementary investigations.
Indeed, evidence suggests that underinvestigation is particularly
common in non-specialist settings. For example, a large study com-
paring over 5000 patients with LOAD and YOD demonstrated that
extended investigations including extensive cognitive evaluation by
a neuropsychologist, language assessment by a speech therapist,
structural brain imaging with MRI, lumbar puncture with analysis
of dementia biomarkers in CSF, electroencephalography or func-
tional brain imaging with SPECT/ PET were generally required to
reach diagnosis in the young-onset group.25
With this in mind, improving recognition and knowledge of
YOD for primary care physicians and non-specialists where such
facilities may be scarce must be an important goal. A new deci-
sion-making tool developed by the Young Dementia Network UK
has been specifically designed to guide diagnosis and raise aware-
ness of key red flags to diagnosis.74 Equally, ensuring access to
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training and demonstration of key competencies should be a key
consideration for such services. In regional, rural, and remote
areas, initiatives to expand consultation services using videoconfer-
encing and telementoring has been demonstrated to be a valuable
tool and could be envisaged for complex case discussion and
imaging reviews.75
The evidence presented here supports the view that a multidis-
ciplinary/multispecialist assessment within a specialist YPD service
or centre is necessary for establishing YOD diagnosis and integra-
tion between specialists and partnership with a broad range of ser-
vices (including third sector) is vital to help connect patients and
their families with support at home and in their community. This
approach is emphasised in the view from professional bodies.76
Facilitating consultation with experts more widely to those in
rural areas who have limited access to key diagnostic tools is a
vital part of this outreach in order to ensure alignment of process
across services. Identifying a minimum standard for accuracy in
diagnosis is likely to be helpful in this regard.
Furthermore, given the substantial burden of assessment out-
lined, consulting YPD about how best to undertake assessment
and diagnosis would further guide good practice, and user and
family organisations should be supported to participate in policy
making and service planning. This approach overlaps with the
best practice model of care developed by the Young Dementia
Network UK which is supported by key stakeholders77 and forms
the basis of current research to improve diagnosis for YPD
(http://www.ucl.ac.uk/psychiatry/the-angela-project).
Strengths and limitations
A scoping literature search identified the latest advances regarding
diagnosis of dementia in younger people. Evidence was sparse and
mostly involved expert opinion pieces and key practice pointers
in the field. The limitations of the current evidence base include
the potential bias of information from experts depending on speci-
ality and the lack of controlled clinicopathological studies employ-
ing trials of clinical guidelines already in use for dementia in
younger populations. Limited information is available about stand-
ard approaches to assessment of YOD in mental health services
where understanding key elements of best practice would be
valuable.
Implications
The quality of evidence identified in this review is variable with the
majority provided from expert opinion and evidence is lacking on
some topics. Evidence appears weighted towards diagnosis in
FTD and its subtypes and young-onset Alzheimer’s disease.
Accurate diagnosis is crucial in allowing individuals to understand
and manage life with dementia at any age. For YPD, the diagnosis is
‘out of time’ and associated with specific and unique needs. This
review highlights the importance of undertaking a comprehensive
and patient-specific approach to diagnosis of YOD and is intended
to assimilate emerging information from new fields for clinicians.
The literature demonstrates that a clinically rigorous and systematic
approach is necessary in order to avoid mis- or underdiagnosis for
younger people. The review is not intended to be a comprehensive
systematic review, but to provide a guide to psychiatrists and others
in the field about current thinking. With the advent of new disease-
modifying treatments there is an obligation to upskill clinicians in
new imaging techniques and genetics, with the goal of improving
training and practice, and highlights the need for quality indicators
and alignment of diagnostic procedures across clinical settings.
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Appendix 1
A breakdown of the three criteria (defining terms for young-onset, individual dementia diagnoses and terms related to the diagnostic process) and terms
used when searching the search engines for appropriate articles
Group Terms (in title or abstract)
1 Defining terms for young onset TS: ((‘young onset’ OR ‘younger onset’ OR ‘early onset’ OR ‘presenile’ OR ‘working age’ OR ‘YOD’ OR ‘under 65’) NOT
(‘elderly’ OR ‘older’ OR ‘late’))
2 Defining terms for dementia, and
individual diagnoses
TS: (‘dementia’ AND ‘Alzheimer’s’ OR ‘vascular dementia’ OR ‘frontotemporal dementia’ OR ‘Semantic dementia’ OR
‘Huntington’s disease’ OR ‘acquired brain injury’ OR ‘Parkinson’s disease’ OR ‘Creutzfeldt-Jakob’ OR ‘CJD’ OR
‘Lewy bodies’ OR ‘Picks disease’ OR ‘cognitive impairment’ OR ‘neurocognitive disorder’ OR ‘Posterior Cortical
Atrophy’)
3 Defining terms for the diagnostic
process
TS: (‘diagnosis’ AND ‘assessment’ OR ‘diagnostic’ OR ‘GP’ OR ‘misdiagnosis’ OR ‘misdirection’ OR ‘referral’ OR
‘clinicians’ OR ‘biomarkers’ OR ‘neuropsych’ OR ‘neuroimage’)
TS, Searching the Topic field.
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